BI 836909

Drug Profile

BI 836909

Alternative Names: AMG 420

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim; Micromet Inc
  • Developer Amgen; Boehringer Ingelheim
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Apoptosis stimulants; B-cell maturation antigen modulators; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 01 Sep 2016 BI 836909 licensed to Amgen worldwide
  • 07 Mar 2012 Micromet Inc has been acquired by Amgen
  • 02 Mar 2012 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top